Overall Market for Acute Heart Failure Therapies Will More Than Double to $768 Million in 2017, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Biogen Idec's Adentri and Merck's rolofylline are the most promising therapies in development for acute heart failure, according to surveyed experts. Scios/Johnson & Johnson's Natrecor and Daiichi Sankyo's Hanp have also added considerable value to the acute heart failure market in recent years and will continue to do so through 2017.
The new Pharmacor report entitled Acute Heart Failure finds that the launch of Adentri and rolofylline, along with EKR Therapeutics' ularitide, will be the primary drivers of growth in the acute heart failure drug market over the next decade. Growth will also be driven by an increase in the number of diagnosed events of acute heart failure as a result of the rising population of elderly people, improved diagnosis methods and increased survival following acute myocardial infarction.
The report forecasts that the acute heart failure market will more than double, from $354 million in 2007 to $768 million in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for acute heart failure is modestly sized because the dominant therapies -- loop diuretics and nitrate vasodilators -- are some of the oldest agents in cardiology and, as a result, are generically available and inexpensive.
"Despite the significant unmet need, research and development pipelines for acute heart failure are not as robust as those for other cardiovascular indications such as hypertension and dyslipidemia," said Decision Resources Analyst Amir Mobasheri. "As a result, any novel agent that can demonstrate improvements in safety and mortality and shows efficacy in preventing future acute heart failure episodes will be well received by physicians and patients."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained
in this document may be trademarks or registered trademarks of their
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved